FDA approved CD38 monoantigendarZALEX (daratumumab) in a joint with kafezome and dexamisson to treat recurring or refractic multiple myeloma.

Danish biopharmaceutical company Genmab has announced that the U.S. Food and Drug Administration (FDA) has approved its CD38 monoantigenist DARZALEX (daratumumab) in a joint treatment with Kafezome and Desemisson (DKD) to treat adult patients with relapsed/refractic multiple myeloma after 1-3 treatments.
Van de Winkel, chief executive of Genmab, said: "We are pleased to have been approved by the FDA and daratumab is now the first CD38 antibody to be approved for use in association with Kafezome.
" about daratumab Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity with CD38 molecules, which are highly expressed on the surface of multiple myeloma cells.
daratumab triggers the body's own immune system to attack cancer cells, causing the rapid death of tumor cells.
Photo Source: About Multiple Myeloma Multiple Myeloma is an incurable blood cancer that begins in the bone marrow and is characterized by excessive proliferation of plasma cells.
multiple myeloma is the third most common blood cancer in the United States after leukemia and lymphoma.
2018, about 160,000 people worldwide were diagnosed with multiple myeloma and 106,000 died from the disease.
.